Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve ...

Anosheh Afghahi, MD, explains how integrated health technologies can improve clinical trial matching, efficiency, and equity.

Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.

Near-complete TTR stabilization with acoramidis translated into a moderate, clinically meaningful KCCQ-OS benefit at 30 months (LSM difference 9.9 points; P < .001). Treatment effects emerged early, ...

Trump's agenda reverses Biden-era policies on drug costs and ACA, hinting at a shift in priorities. Key Biden initiatives, like the $35 insulin cap and Medicare drug price negotiations, remain ...

Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...

Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, ...

Mean LDL-C at 6 months was 76.3 vs 85.6 mg/dL, yielding an adjusted difference of −6.62 mg/dL and higher attainment of LDL-C <50 mg/dL. Intervention uptake increased intensive and combination ...

Workforce expansion authorized after the 2024 Harlem outbreak remains incomplete, with 35 staff onboard versus a planned 56, leaving gaps in inspection and response throughput. A second lethal cluster ...

LATITUDE PsO 3001/3002 (n = 693; n = 1108) showed ~70% of patients achieving clear or almost clear skin at week 16 versus 11% to 13% on placebo and 30% to 32% on apremilast. Depth of response was ...

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at ...

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...